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ABSTRACT
Background: Glioblastomas (GBM) present a high cellular heterogeneity with 
conspicuous necrotic regions associated with hypoxia, which is related to tumor 
aggressiveness. GBM tumors exhibit high glycolytic metabolism with increased lactate 
production that is extruded to the tumor microenvironment through monocarboxylate 
transporters (MCTs). While hypoxia-mediated regulation of MCT4 has been characterized, 
the role of MCT1 is still controversial. Thus, we aimed to understand the role of hypoxia 
in the regulation of MCT expression and function in GBM, MCT1 in particular.
Methods: Expression of hypoxia- and glycolytic-related markers, as well as MCT1 and 
MCT4 isoforms was assessed in in vitro and in vivo orthotopic glioma models, and also in 
human GBM tissues by immunofluorescence/immunohistochemistry and Western blot. 
Following MCT1 inhibition, either pharmacologically with CHC (α-cyano-4-hydroxynnamic 
acid) or genetically with siRNAs, we assessed GBM cell viability, proliferation, metabolism, 
migration and invasion, under normoxia and hypoxia conditions.
Results: Hypoxia induced an increase in MCT1 plasma membrane expression in 
glioma cells, both in in vitro and in vivo models. Additionally, treatment with CHC and 
downregulation of MCT1 in glioma cells decreased lactate production, cell proliferation 
and invasion under hypoxia. Moreover, in the in vivo orthotopic model and in human 
GBM tissues, there was extensive co-expression of MCT1, but not MCT4, with the GBM 
hypoxia marker CAIX.
Conclusion: Hypoxia-induced MCT1 supports GBM glycolytic phenotype, 
being responsible for lactate efflux and an important mediator of cell survival and 
aggressiveness. Therefore, MCT1 constitutes a promising therapeutic target in GBM.
BACKGROUND
Tumor cells present several biological alterations 
known as cancer hallmarks [1]. Recently, metabolic 
reprogramming, namely “Warburg effect”, was considered 
a major cancer feature [2-4], in which glycolytic 
phenotype is favored. The glycolytic phenotype observed 
in tumor cells is also an adaptive consequence of tumor 
hypoxic microenvironment [4]. The presence of tumor 
hypoxia induces stabilization of hypoxia-inducible factor 
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1 alpha (HIF-1α) [5], which leads not only to induction 
of angiogenesis, but also upregulation of glycolytic 
metabolism, to maintain the ATP production necessary for 
cell survival and proliferation [6]. The increased lactate 
production together with diminished vascular dispersion 
of CO2 contributes to tumor hypoxic acidosis [6], which is 
associated with increased aggressiveness, poor prognosis 
and acquired resistance [7].
Glioblastoma (GBM) is the most common and lethal 
primary brain tumor [8]. Despite the observed progress 
in therapy, prognosis of GBM patients is still dismal, 
presenting an overall survival of approximately 15 months 
[9]. Thus, novel and more effective therapeutic approaches 
are needed to overcome this scenario. GBMs are known 
to exhibit metabolic remodeling [10], with an increase 
in glycolysis of about 3-fold, compared to normal brain 
tissue [11]. Additionally, GBM cells have increased lactate 
production [12], which is further transported to the tumor 
microenvironment through monocarboxylate transporters 
(MCTs) [13].
MCTs belong to the solute carrier family 16 
(SLC16), which is composed by 14 members, being 
MCT1-MCT4 responsible by the proton-coupled 
transport of monocarboxylates [14]. The activity of these 
transporters is critical for metabolic communication 
between cells and they have different properties 
and tissue distributions, according to their kinetics 
characteristics [15]. According to the distinct affinities 
of MCT isoforms for lactate, MCT1 and MCT4 are 
described to mediate lactate efflux, contributing to tumor 
pH regulation [15]. Several studies from our group and 
others reported up-regulation of MCTs in different solid 
tumors [16]. Recently, we demonstrated that MCT1/4 
and their chaperone CD147 are up-regulated on GBMs 
and presented evidence for the role of MCT1 in the 
hyper-glycolytic and acid-resistant phenotype of these 
tumors [17].
There is increasing evidence that MCT expression 
is altered (at transcriptional and post-transcriptional 
levels) in response to metabolic demands [18]. Hypoxia 
is a common feature of solid tumors, including GBMs, 
and it promotes tumor aggressiveness, leading to poor 
patient outcome [19]. MCT4 expression was described 
to be regulated by hypoxia in several cancer types, 
including bladder [20], cervix [21] and breast [22, 
23]. Also, in normal tissues, MCT4 was described to 
be upregulated after chronic hypoxia, being increased 
in heart muscle [24], trophoblast [25] and adipocyte 
[26] cells in a HIF-1α dependent mechanism. In 
fact, following elegant functional studies, Ullah and 
collaborators, showed that MCT4, but not MCT1 
promoter was activated by hypoxia and that this 
response was mediated by HIF-1α [27]. Nevertheless, 
it was observed that MCT1 increased in neuronal, 
astrocytes and endothelial cells upon left middle 
cerebral artery occlusion [28], as well as in adipocytes 
exposed to hypoxia [26]. Thus, the regulation of 
MCT1 under hypoxia conditions appears to be not 
well understood and even controversial. Therefore, in 
the present study we aim to understand how hypoxia 
regulates MCT1 activity and expression and how this 
associates with aggressiveness and survival of GBM 
cells.
RESULTS
Hypoxia increases MCT1 plasma membrane 
expression in glioma cells in vitro
In the present study, we used two known glioma 
cell lines with distinct metabolic behavior [17]. U251 
cells exhibit a more glycolytic phenotype and present 
high plasma membrane expression of MCT1, CD147 
and GLUT-1, as well as cytoplasmic HKII expression 
compared to SW1088 cells, under normoxia conditions 
(Figure 1A and 1B). In U251 cells, expression of GLUT-
1, HKII and CD147 was similar in both normoxia and 
induced hypoxia conditions, while there was a clear 
increase of MCT4 and CAIX in hypoxia (Figure 1A and 
1B, Table 1), and a slight increase in MCT1 expression 
(Figure 1B, Table 1). Regarding SW1088 cells, we 
observed an increased expression of the metabolic 
markers, with exception of MCT4 that decreased in 
hypoxia (Figure 1A and 1B, Table 1). We also observed 
MCT1, CD147 and GLUT1 increase staining in plasma 
membrane expression under hypoxia, compared to 
normoxia (Figure 1A and 1B, Table 1). Hypoxia induced 
conditions were supported by nuclear expression of the 
hypoxia marker HIF-1α (Figure 1A and 1B). To confirm 
the increase in plasma membrane expression of MCT1, 
MCT4 and their chaperone CD147, cell fractionation with 
plasma membrane isolation was performed. As observed 
in Figure 1C, there is an increase in MCT1 and CD147 
plasma membrane expression in SW1088 cells, with no 
MCT4 plasma membrane expression.
In U251 cells, the increase in MCT4 plasma 
membrane expression was evident in hypoxia, whereas 
there was only a slight increase to MCT1 and no changes 
in CD147 (Figure 1C). Hypoxia conditions induced up-
regulation of glycolytic proteins and MCTs in glioma 
cells, with higher intensity for the most oxidative cell 
line SW1088. Subsequently, the extracellular glucose and 
lactate levels were analyzed to confirm the induction of the 
glycolytic phenotype. As expected, an increase in glucose 
consumption and lactate extrusion was observed in both 
cell lines (Figure 1D). In SW1088 cells, a metabolic switch 
towards a more glycolytic metabolism was confirmed by 
the shift ratio extruded lactate/consumed glucose from 0.5 
under normoxia to 0.8 under hypoxia. At variance, in the 
more glycolytic U251 cells the ratio remains close to 1 in 
both conditions (Figure 1D), despite the hypoxia related 
increase in glucose consumption and lactate secretion.
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Figure 1: Protein levels, cellular localization and glycolytic metabolism of glioma cells under hypoxia. A. Cellular 
localization of the different metabolic markers and monocarboxylate transporters in normoxic and hypoxic regions, by immunofluorescence; 
pictures were taken using the microscope Olympus BX16 at 400x. B. Protein levels under normoxia and hypoxia in glioma cells by Western 
blot analysis; MCT1 50kDa, MCT4 44kDa, CD147, high glycosylated (HG) 52-42kDa and low glycosylated (LG) 34kDa; GLUT1 52kDa, 
HKII 95kDa, CAIX 52kDa, HIF-1α 110kDa and β-Actin 42kDa. C. Protein levels of cytoplasm and plasma membrane fractions for MCT1, 
MCT4 and CD147; β-actin and ATPase (90kDa) were used as loading controls for cytoplasm and plasma membrane fractions, respectively. 
D. Glucose consumption and lactate secretion in glioma cells under normoxia and hypoxia conditions; results are the mean±SEM of at least 
three independent experiments, each one in triplicate; *** p≤0.001 normoxia vs hypoxia.
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MCT1 mediates lactate efflux in glioma cells
In order to evaluate the role of MCT1 and 4 as 
contributors to the glycolytic phenotype in hypoxia, 
MCT pharmacological inhibition was performed with 
CHC (IC
50
/2 value) and downregulation of MCT1 
and MCT4 isoforms by siRNA. Treatment with either 
CHC or siMCT1in SW1088 cells led to a decrease 
in extracellular lactate only in hypoxia (Figure 2). In 
U251 cells, treatment with CHC decreased extracellular 
lactate in both normoxia and hypoxia (Figure 2). Similar 
findings were found for MCT1 downregulation in both 
conditions, however inhibition of MCT4 alone led 
to a slight increase in extracellular lactate (Figure 2). 
Combined downregulation of both MCT isoforms (MCT1 
and MCT4) decreased extracellular lactate with a profile 
similar to MCT1 silencing (Figure 2A). Importantly, 
specific downregulation of MCT1 had the same effect 
of CHC on lactate secretion, indicating that MCT1 has 
an important role in the maintenance of the glycolytic 
phenotype in hypoxic conditions. Downregulation of 
MCTs was confirmed by Western blot (Supplementary 
Figure S1A) and immunofluorescence (Supplementary 
Figure S1B and S1C). We observed an interdependence 
of MCT1/CD147, since downregulation of MCT1 led to a 
decrease in CD147 plasma membrane expression in both 
cell lines, whereas downregulation of MCT4 in U251 cells 
did not change the expression and cellular localization of 
CD147 (Supplementary Figure S1B and S1C).
MCT1 inhibition decreases glioma cell viability 
and proliferation under hypoxia
The role of MCT1 on glioma viability and 
proliferation was also evaluated upon metabolic remodeling 
induced by hypoxia. Treatment with CHC decreased 
significantly cell growth in both cell lines under hypoxia 
(Figure 3A), while only a slight decrease was observed for 
U251 cells under normoxia. Additionally, downregulation 
of MCT1 in SW1088 cells, only decreased cell growth 
under hypoxia (Figure 3A), while in U251 cells, MCT1 
silencing led to a significant decrease in cell growth in both 
normoxia and hypoxia (Figure 3A).
Treatment with CHC only decreased cell proliferation 
under hypoxia (Figure 3B) and MCT1 downregulation 
decreased cell proliferation in both cell lines in both 
normoxia and hypoxic conditions (Figure 3B). Furthermore, 
it was observed that cell death did not increase in hypoxia 
either with CHC treatment or MCT1 downregulation, with 
only a tendency for CHC treatment in U251 cells, but 
without statistical significance (Figure 3C).
MCT1 contributes to glioma migration and 
invasion under hypoxia 
The role of MCT1 on cell aggressiveness was 
evaluated by assessing cell migration and cell invasion 
upon inhibition of MCT1 activity and expression.
In SW1088 cells, treatment with CHC decreased 
cell migration in both conditions (Figure 4A), with a 
significant decrease from normoxia to hypoxia. Only 
treatment with CHC under hypoxia promoted a significant 
decrease in cell invasion (Figure 4B). Additionally, 
MCT1 silencing decreased significantly cell migration 
(Figure 4A) and invasion (Figure 4B) in hypoxia but not 
under normoxia.
For U251 cells, treatment with CHC decreased 
significantly cell migration (Figure 4A) but not 
invasion (Figure 4B) in both normoxia and hypoxia. 
Downregulation of MCT1 led to a significant decrease in 
cell migration (Figure 4A) and cell invasion (Figure 4B) 
under normoxia, however under hypoxia conditions, only 
a decrease in cell invasion was verified (Figure 4B).
MCT1 expression increases in hypoxic regions in 
3D cultures and in orthotopic glioma models
To further support the previous results, we 
performed SW1088 3D cultures (spheroids), and observed 
an increase in MCT1 plasma membrane expression in 
Table 1: Summary of the results of expression of MCTs and other metabolic markers in hypoxia vs normoxia 
conditions in glioma cell lines
Hypoxia vs Normoxia
U251 SW1088
MCT1 increased (PM) increased (PM)
MCT4 increased (PM) decreased (cytoplasm)
CD147 similar (PM) increased (PM)
GLUT1 similar (PM) increased (PM)
HKII similar increased
CAIX increased increased
PM- plasma membrane
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the spheroid core (less oxygenated region), whereas 
MCT4 expression remained at the periphery and was 
cytoplasmic (Figure 5A). Additionally, using the CAM 
assay, we observed in U251 ex ovo microtumors that 
MCT1 plasma membrane expression was higher in the 
region that was positive for CAIX, while MCT4 presented 
a weak cytoplasmic expression (Figure 5B). The U87-MG 
cell line was used in the intracranial model, since is the 
well described to form in vivo tumors that better mimic 
the human GBM behavior with heterogeneous regions, 
exhibiting necrotic regions and angiogenic features [29]. 
Characterization of MCT1 and MCT4 distribution in 
U87-MG brain tumors showed a weak expression in both 
isoforms, and a negative CAIX expression, in regions 
close to blood vessels (normoxic regions) (Figure 5C). 
Particularly, in the regions positive to CAIX expression 
(hypoxic regions), we observed a strong co-localization 
of MCT1 with CAIX (Figure 5C). In contrast, most CAIX 
positive cells did not co-localize with MCT4 in these 
intracranial tumors (Figure 5C).
MCT1 plasma membrane expression is 
associated with hypoxic regions of GBM tissues
To support the above finding, a total of 45 GBM 
cases were assessed for MCT1, MCT4 and chaperone 
CD147 expressions, as well as for different glycolytic 
metabolism-related proteins, GLUT-1, HKII, CAIX 
and HIF-1α in normoxic regions (vascularized regions, 
distant from necrotic areas) and hypoxic regions (peri-
necrotic areas). The expression of these markers was also 
evaluated in 17 non-tumoral adjacent tissues. In the non-
Figure 2: Lactate secretion upon MCT inhibition. Extracellular lactate levels upon MCT pharmacological (CHC) and genetic 
inhibition (siRNA) in SW1088 and U251 cells under hypoxia conditions; results are the mean±SEM of at least three independent 
experiments, each one in triplicate; *p<0.05 compared CHC or downregulation vs control condition.
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tumoral regions, astrocytes and neurons were negative 
for all markers (Figure 6), and expression of MCT1, 
CD147 and GLUT-1 was present in capillaries and small 
vessels (Figure 6). In GBM tissues, CAIX, GLUT-1 and 
HIF-1α presented a focal expression in hypoxic regions, 
with 88.9%, 88.9% and 60% positivity, respectively 
(Table 2; Figure 6). MCT1 total (cytoplasm/membrane) 
expression increased in hypoxic regions of GBMs (62.2%) 
(Table 2; Figure 6), with 71.1% of cases presenting 
plasma membrane expression (Table 2; Figure 6). 
MCT4 and CD147 were expressed in both normoxic and 
hypoxic regions (82.2% and 91.1%, respectively; Table 
2, Figure 5), however only 20% of the cases presented 
MCT4 plasma membrane expression in hypoxic regions 
(Table 2). The MCT chaperone CD147 exhibited a higher 
expression at the plasma membrane, with 37.8% of cases 
Figure 3: Effect of MCT1 inhibition on cell proliferation and cell death of glioma cells under hypoxia. Cell proliferation 
in SW1088 and U251 cells under hypoxia by A. trypan blue and B. BrdU assay, respectively. C. Cell death in SW1088 and U251 cells 
under hypoxia by AnnexinV/PI flow cytometry analysis; results are the mean±SEM of at least three independent experiments, each one in 
triplicate; To MCT downregulation graphs the results were compared to scramble condition which was normalized to 100% represented as 
grey line; *p<0.05, **p≤0.01 *** p≤0.001; # p<0.05 compared normoxia vs hypoxia at respective conditions.
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Figure 4: Cell migration and invasion behavior upon MCT1 under hypoxia. Cell migration A. and cell invasion B. of 
glioma cells under normoxia and hypoxia after MCT1 downregulation and MCT activity inhibition with CHC. Pictures were taken at 
40x magnification (migration) and 200x magnification (invasion) in an Olympus BX16 microscope. Results represent the mean±SEM of 
three independent experiments. The different conditions of silencing were compared to scramble conditions that was normalized to 100% 
(represented as grey line); *p<0.05, **p≤0.01 *** p≤0.001; # p<0.05 compares normoxia vs hypoxia at respective conditions.
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Figure 5: MCT1 and MCT4 expression distribution in 3D culture and in in vivo glioma models. A. Immunohistochemical 
expression of MCT1, MCT4 and GLUT1 in SW1088 spheroids. Pictures are representative of n=10 spheroids and taken using the 
Olympus BX16 microscope at 40x, 100x and 400x magnification; B. MCT1, MCT4 and CAIX expression in U251 microtumors by 
immunohistochemistry. Pictures are representative of n=8 eggs and taken using the Olympus BX16 microscope, at 40x, 200x and 400x 
magnification; C. MCT1 and MCT4 expression in in vivo U87-MG intracranial tumors by immunofluorescence. Pictures are taken at 100x 
and highlighted at 400x for MCT1, MCT4 and CAIX in normoxic (close to blood vessels) and hypoxic regions (distant from blood vessels, 
positive for the hypoxia marker CAIX).
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Figure 6: Immunohistochemical expression of monocarboxylate transporters, CD147, GLUT1, HKII, CAIX and 
HIF-1α in GBM and normal adjacent tissues. Expression of MCT1, MCT4, CD147 (MCT1/4 chaperone), glycolytic markers 
(HKII, GLUT1) and hypoxia markers (CAIX, HIF-1α) in neoplastic and non-neoplastic of GBM patient tissues, by immunohistochemistry. 
Pictures were obtained using the Olympus BX61 microscope, at 100x and the inserts at 400x magnification.
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positive only in hypoxic regions (Figure 6; Table 2). The 
glycolytic marker HKII presented a ubiquitous expression 
with 44.4% of total cases positive only in hypoxia 
(Table 2; Figure 6).
In the immunostaining heat map (Figure 7A), we 
observed that MCT1 expression increases from normoxic 
to hypoxic regions, showing higher plasma membrane 
expression in hypoxic regions together with the hypoxic 
(CAIX) and glycolytic (GLUT-1) markers. We verified 
that the cases with positivity in normoxic regions maintain 
the expression in hypoxic regions. Additionally, we found 
an association of MCT1 plasma membrane expression in 
hypoxic regions of GBM with co-expression of HIF-1α 
and CAIX, and also a tendency to associate with GLUT-1 
(Table 3). Moreover, co-localization of MCT1 with CAIX 
at the plasma membrane in hypoxic regions of the GBM 
tissues was confirmed by immunofluorescence (Figure 7B). 
Importantly, clinical specimens of GBMs validated the 
previous findings using in vitro and in vivo GBM models, 
in which MCT1 is enriched in hypoxic regions, and co-
localize with surrogate markers of hypoxia.
DISCUSSION
Glycolytic metabolism of tumor cells has been 
described as an adaptive mechanism to intermittent 
hypoxia present in pre-malignant lesions [4, 6]. Yet, 
regulation of MCTs in hypoxia is not well understood, 
with controversial results, namely for MCT1 [20-22, 26, 
27]. GBM are characterized by the presence of necrosis 
that seems to be associated with hypoxia regions [30], 
and these high levels of hypoxia have been implicated in 
resistance to chemo- and radiotherapy [31]. In a previous 
study, we reported up-regulation of MCT1, MCT4 and 
CD147 in a series of GBM compared to normal tissues 
[17]. Herein, we intended to understand the role of 
hypoxia in the regulation of MCT expression and activity 
in GBM.
Analyzing two cell lines with different metabolic 
phenotypes, namely a less glycolytic SW1088 cell line 
(lower MCT1 plasma membrane expression) and a 
more glycolytic U251 cell line (higher MCT1 plasma 
membrane expression), we observed distinct sensitivities 
to the classical pharmacological MCT inhibitor CHC 
[17]. In the present study, we showed that hypoxia led to 
MCT1 and CD147 up-regulation, but not MCT4, at the 
cell plasma membrane of SW1088 cells. However, there 
is compelling evidence in the literature demonstrating 
that MCT4 is the isoform which is upregulated in the 
hypoxic regions of the tumors, being responsible for 
lactate efflux to the tumor microenvironment, being 
associated with several malignant features [20-23, 27]. 
Upregulation of MCT4 levels in hypoxia was observed 
in bladder cancer [20] and an increase in MCT4 plasma 
membrane expression was also observed in breast 
cancer cells [22]. Importantly, Ullah et al. reported that 
only MCT4 is induced by hypoxia, since only this MCT 
isoform contains hypoxia response elements (HRE) for 
HIF-1α [27]. At variance with these authors, we showed 
that MCT4 expression decreased with hypoxia in SW1088 
cells. Accordingly, it was described that MCT4 expression 
decreased after chronic hypoxia in the plantaris muscle 
[24]. Moreover, a recent study in adipocytes demonstrated 
that MCT1, but not MCT4 protein expression increased 
in hypoxia [26]. Here, a slight increase in MCT1 was 
observed in hypoxia in the highly glycolytic cell line 
(U251), however an increase in MCT4 plasma membrane 
expression was also verified, supporting the study of Ullah 
et al., [27]. Additionally, an increased MCT1 and MCT4 
plasma membrane density was reported in brain cells 
under hypoxia [22], which also corroborates our results 
(Figure 8).
Table 2: Distribution of metabolic markers and MCT/CD147 expression in normoxic and hypoxic regions of 
glioblastoma tissues
n (total) Total expression Plasma membrane expression
Hypoxia Normoxia and 
Hypoxia
Hypoxia Normoxia and 
Hypoxia
n (%) n (%) n (%) n (%)
MCT1 45 28 62.2 17 37.8 32 71.1 8 17.8
MCT4 45 8 17.8 37 82.2 9 20.0 10 22.2
CD147 45 4 8.9 41 91.1 17 37.8 26 57.8
GLUT-1 45 40 88.9 4 8.9 39 86.7 2 4.4
CAIX 45 40 88.9 2 4.4 32 71.1 0 0.0
HKII 45 20 44.4 25 55.6 na* - na* -
HIF-1α 45 27 60.0 0 0.0 na* - na* -
* na: not applicable
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Figure 7: Association of MCTs and CD147 expression with hypoxia markers (GLUT-1 and CAIX) in GBMs. A. Heat 
map representation of the monocarboxylate transporter and chaperone expression, and hypoxic markers for the 45 GBM tissues evaluated 
under normoxia and hypoxia regions. Blue color corresponds to negative or cytoplasm expression and red corresponds to plasma membrane 
expression; B. Plasma membrane expression of the hypoxia marker CAIX (in green) and MCT1 (in red) in GBM tissue. Co-localization of 
MCT1 and CAIX at the plasma membrane (orange). Pictures were taken using the microscope Olympus BX16 at 100x (I), 200x (II) and 
400x (III).
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Up-regulation of MCT1 contributes to the glycolytic 
phenotype of brain cancer cells, which was supported by 
the observed increase in glucose consumption and lactate 
production, as well as overexpression of GLUT1 and 
HKII in SW1088 cells in hypoxia. In the present work, 
we also investigated the effect of MCT activity inhibition 
in human glioma cell lines in hypoxia, using the lactate 
transport inhibitor CHC and also through MCT1 and 
MCT4 mRNA downregulation (siRNA). MCT1 inhibition 
induced a decrease in lactate production in SW1088 
cells in hypoxia compared to normoxia conditions. This 
was anticipated, since hypoxia induces the glycolytic 
phenotype in SW1088 cells, leading to increased MCT1 
plasma membrane expression. Additionally, MCT1 
silencing in U251, but not MCT4, decreased lactate 
production in both normoxia and hypoxic conditions. 
Although previous reports suggested that MCT4 is the 
major lactate transporter in hypoxic cells [21, 27], in 
our cell models we demonstrate that MCT1 mediates the 
lactate efflux in hypoxic conditions. In line with this, a 
recent study with colon adenocarcinoma cells showed 
that MCT1 silencing in hypoxia decreased lactate efflux 
[32]. Furthermore, our results show that CHC inhibited 
preferentially MCT1 rather than MCT4 isoform, which 
can be explained by the different Ki values for these two 
isoforms [33, 34].
It is known that hypoxia contributes to the 
glycolytic-acidic resistant phenotype of tumor cells [6], 
contributing to increased cell growth and survival, due 
to induction of several malignant features like migration 
and invasion. Accordingly, we studied the contribution of 
MCTs, particularly MCT1, to cell growth, survival and 
invasiveness capacity under hypoxia (Figure 8). Inhibition 
of MCT1 activity and expression led to a decrease in 
viability and cell proliferation, however it did not promote 
cell death in hypoxia-induced SW1088 cells. In fact, some 
studies have been demonstrating the importance of lactate 
transport via MCT1 in the promotion of cell proliferation 
and tumor growth [35, 36].
GBM have an intrinsic high invasive capacity [37], 
producing high amounts of lactate [12] that contribute to 
the acidic microenvironment, and consequent promotion 
of cell migration and invasion. It is already described that 
inhibition of MCT activity decreases breast cancer cell 
migration [36] and the invasive capacity of GBM [38]. 
Additionally, it was described that MCT1 is the mediator 
of lactate efflux and consequently promotes the invasive 
phenotype of GBM [17]. However, the role of MCTs in the 
promotion of migration and invasion under hypoxia was 
not assessed. In the present study, MCT1 downregulation 
in hypoxia was associated with a decrease in cell invasion 
in both cell lines tested. However, a decrease in cell 
migration was only observed in SW1088 cells. Since 
MCT4 does not appear to participate in lactate efflux even 
at hypoxic conditions in our cell model, the increase in cell 
migration after MCT1 downregulation could be explained 
due to the strong association of MCT4 with β1-integrin 
on the cell movement capacity [39]. Additionally, 
the effect observed can be a mechanism mediated by 
hypoxia, since it is known that under these conditions 
Table 3: Association of MCT1 plasma membrane expression in hypoxic regions with different hypoxia-inducible 
metabolic markers in glioblastomas
MCT1
n PM* (%) p
MCT4
negative/cytoplasm 36 27 60.0
0.250
positive/PM 9 5 11.1
CD147
negative/cytoplasm 28 20 44.4
0.952
positive/PM 17 12 26.7
GLUT-1
negative/cytoplasm 6 4 8.9
0.067
positive/PM 39 28 62.2
CAIX
negative/cytoplasm 13 9 20.0
0.031
positive/PM 32 23 51.5
HKII
negative 20 20 44.4
0.141
positive 25 12 26.7
HIF-1α
negative 18 16 35.6
0.032
positive 27 16 35.6
* positivity for MCT1 plasma membrane (PM) in hypoxic regions of glioblastomas
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there is up-regulation of several proteins associated with 
cell migration and invasion [40]. Furthermore, lactate 
transport in cancer cells could be mediated by a different 
lactate transporter, namely the sodium monocarboxylate 
transporter 1 (SMCT1) [41]. Although its expression 
is not well described in tumors, we cannot exclude 
the possible up-regulation of SMCT1 in hypoxia as a 
compensatory mechanism for cell survival. Regardless, 
our study demonstrates that MCT1 is a mediator of the 
aggressiveness phenotype of GBM cells in hypoxia, 
since there was a decrease in cell invasion after MCT1 
downregulation (Figure 8).
Based on our findings, we hypothesize that up-
regulation of MCT1 in GBM cells can be an adaptation 
to changes in oxygen levels, helping cells to be prepared 
for episodes of net release of lactate, alternating with 
episodes of net uptake. In fact, our results with 3D cultures 
(SW1088 spheroids), ex ovo U251 microtumors and U87-
MG brain tumors support the role of MCT1 as mediator 
of lactate efflux under low oxygen level conditions. 
Although, our results showed ubiquitous expression of 
MCT1 in SW1088 spheroids and in vivo glioma models, 
MCT1 plasma membrane expression is stronger in 
hypoxic regions and co-localizes with CAIX expression 
in vivo glioma models.
Furthermore, the importance of enhanced MCT1 
expression in hypoxia as a gatekeeper of lactate efflux 
was confirmed in a series of 45 GBM patients. The 
present study demonstrates that there is a shift from 
cytoplasm to plasma membrane expression of MCT1 in 
GBM tissues, while MCT4 is present in higher amounts 
in the cytoplasm, despite the increase in both MCT1 and 
Figure 8: MCT1 as a mediator of aggressiveness at hypoxic regions in glioblastomas. In normoxic tumor cells, MCT1 is 
expressed at the plasma membrane, whereas MCT4 remains at the cytoplasm. Hypoxia induces upregulation of MCT1 plasma membrane 
expression, which is responsible for lactate efflux. Inhibition of MCT1 expression or activity impairs lactate secretion, contributing to a 
decrease in cell proliferation, cell migration and invasion.
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MCT4 expression in hypoxia (Figure 8). Additionally, 
MCT1 plasma membrane expression was associated with 
positivity for HIF-1α and CAIX in hypoxic regions. A 
previous report in rat brain tumors described that MCT4 
expression was located in the center of the tumor (hypoxic 
area), while MCT1 was mainly at the periphery [42]. 
On the other hand, Kaanders et al., demonstrated that 
MCT1 was present in hypoxic regions in head and neck 
tumors and was associated with CAIX expression [43]. 
Although MCT4 is the isoform that is described to be 
induced by hypoxia [27], a recent study by Feron et al. 
indicates that hypoxia also induced an increase in MCT1 
mRNA levels in breast cancer [32]. Additionally, hypoxia 
induced MCT1 protein expression, but not MCT4, in 
human adipocytes [26]. Altogether, these findings suggest 
that besides MCT4, MCT1 expression is also regulated 
by hypoxia, likely supporting the maintenance of the 
glycolytic phenotype of GBM by mediating lactate efflux 
(Figure 8).
To support our results, we studied in parallel the 
expression of glycolytic markers (GLUT-1 and HKII) and 
hypoxia markers (CAIX and HIF-1α), and observed that 
CAIX, HIF-1 and GLUT-1 expression was restricted to 
hypoxic regions. These results are supported by previous 
studies reporting that HIF-1α [44], GLUT-1 [45] and 
CAIX [46] expression was increased in GBM compared 
to low grade gliomas and that they are associated with 
necrotic regions (hypoxic regions). In the present study, 
MCT1 plasma membrane expression was associated 
with HIF-1α and CAIX in human GBM tissues and a 
similar pattern was observed in CAIX in the CAM U251 
microtumors and U87-MG intracranial mice brain tumors, 
which supports the association of MCT1 expression with 
hypoxic tumors regions. In accordance to our model, 
a study by Pinheiro et al also showed that MCT1 was 
associated to CAIX expression in breast cancer tissues 
[47]. On the other hand, and as expected, several studies 
reported association of MCT4 with hypoxia markers 
in different solid tumors [20, 43, 48]. In head and neck 
[43], and lung cancer [48] higher MCT4 expression was 
observed in regions distant from blood vessels and was 
associated with the hypoxia markers pimonidazole and 
GLUT1, respectively. In the whole, our results support 
that MCT1 expression is regulated by hypoxia, not directly 
through HIF-1α but perhaps through a mechanism that 
could be dependent on HIF-1α activation.
CONCLUSIONS
MCT1 plasma membrane expression is upregulated 
in hypoxia in GBM models and human tissues, playing 
an important role in the maintenance of their glycolytic 
phenotype, which in turn is associated with higher 
aggressiveness. Thus, targeting MCT1, alone or in 
combination with conventional therapy, can constitute an 
attractive strategy for GBM therapy.
MATERIALS AND METHODS
Cell culture and cell lines
U251, SW1088 and U87-MG cell lines used in 
this study were grown in standard conditions [17]. U251 
cells were kindly provided by Professor Joseph Costello, 
California University, Neurosurgery Department, San 
Francisco, USA. SW1088 and U87-MG cells were 
obtained from ATCC (American Type Culture Collection). 
Cell line authentication was performed by IdentiCell 
Laboratories (Department of Molecular Medicine 
(MOMA) at Aarhus University Hospital Skejby in Åarhus, 
Denmark). Genotyping confirmed the complete identity of 
cell lines.
Hypoxia induction
Induction of hypoxia was performed using hypoxic 
chambers (Modular Incubator Chamber (MIC-101), 
billups-rothenberg.inc). Cells were placed in an airtight 
chamber with hypoxic gas mixture 0% O2, 5% CO2 and 
95% N2. The hypoxic chamber was then placed in an 
incubator at 37ºC for a specific period time, according to 
the assay to be carried out. The O2 concentration during 
assays was controlled by an O2 sensor, being below 
1% throughout the experiments. The control normoxic 
conditions were performed in a humidified incubator at 
21% O2, 5% CO2 and 74% N2 for the same period of time.
Antibodies
Antibody details and conditions for 
immunohistochemical, immunofluorescence and Western 
blot assays are summarized in Table 4.
Downregulation of MCTs
Downregulation of MCT1 or MCT4 was performed 
with siRNA (siRNA for MCT1, s580, Ambion; scramble 
siRNA, 4390843, Ambion, siRNA for MCT4, S17417) 
using lipofectamine as a transfection reagent, according 
to the manufacturer’s instructions [49].
Immunohistochemistry
Representative 4μm-thick tissue sections were used 
for immunohistochemical analysis. Immunohistochemistry 
(IHC) for MCT1, CD147 and HIF-1α was performed 
according with the avidin-biotin-peroxidase technique 
(R.T.U. Vectastain Elite ABC kit; Vector Laboratories), 
as previously described [17]. The Ultravision Detection 
System Anti-polyvalent, HRP (Lab Vision Corporation) 
was used for MCT4, GLUT-1, CAIX and HKII, IHC, as 
previously described [17].
Briefly, deparaffinised and rehydrated slides were 
submitted to adequate heat-induced antigen retrieval for 
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20min at 98ºC with 10mM citrate buffer (pH 6.0) for 
MCT1, MCT4, GLUT-1 and CAIX and 1mM EDTA 
buffer (pH 8.0) for CD147, HKII and HIF-1α. After 
endogenous peroxidase inactivation, incubation with the 
primary antibodies was performed overnight for MCT1, 
CD147 and HIF-1α and 2h for MCT4, GLUT-1, CAIX and 
HKII, at room temperature. The immune reactions were 
visualized with 3,3’-diaminobenzidine (DAB+ Substrate 
System; Dako) as a chromogen. Tissue immunostaining 
was evaluated by an experienced neuropathologist (MH). 
Analysis was performed semi-quantitatively considering 
the intensity of staining, according to the following 
score: score 0: negative or weak staining and score 1 
for moderate and strong staining. Score 0 was defined 
as negative and score 1 as positive. The intensity of 
staining was evaluated in regions close to blood vessels, 
here defined as normoxic regions, and, in regions close to 
necrosis, defined as hypoxic regions. Cellular localization 
of staining (cytoplasm/membrane) was also evaluated.
Immunofluorescence
U251 and SW1088 cells were seeded on cover slips at 
a density of 30.000 cells/well, overnight. Briefly, after 24h 
in hypoxia, cells were fixed and permeabilized in methanol 
during 20min. After blocking with 5% bovine serum 
albumin (BSA) for 30min, cells were incubated overnight 
at room temperature with the primary polyclonal antibodies. 
Then, 1h of incubation with the secondary antibody anti-
rabbit-Alexa Fluor 488 (1:500 dilution, A11008, Invitrogen) 
in 5% BSA was performed for MCT4, MCT1, GLUT-1 and 
CAIX and anti-mouse-Alexa Fluor 594 antibody (1:250 
dilution, A11032, Invitrogen) for HKII, CD147 and HIF-
1α. Finally, after washing in PBS, cells were mounted 
in Vectashield Mounting Media with 4’,6-diamidino-2-
phenylindole (DAPI) (Vector Laboratories) and images 
were obtained with a fluorescence microscope (Olympus 
IX81), using the Cell P software. The procedure for GBM 
tissues was similar, performing the antigen retrieval before 
the blocking with 10% BSA for 45min.
Western blotting
Western blot was performed as described previously 
[17]. Incubation with primary antibodies (Table 4) was 
performed overnight at 4ºC. Bound antibodies were 
visualized by chemiluminescence (Supersignal West 
Femto kit; Pierce). β-Actin was used as loading control.
For subcellular fractionation, cells were washed 
with cold PBS and then incubated with 0.5mg/ml of Sulfo-
NHS-LC- Biotin in PBS (3ml/ T75 flask) during 30min 
at 4ºC. Cells were then washed 3x with cold PBS 10mM 
Glycine, followed by cellular lysis. Then, 400μg of protein 
was incubated with 50μl of Streptavidin Agarose Resin 
beads in PBS, overnight with shaking at 4ºC. Proteins 
were centrifuged at 6000rpm for 1min and the supernatant 
(cytoplasm fraction) was collected and quantified. The 
bead pellet (membrane fraction) was washed 4x in 1ml 
lysis buffer, added to 60μl loading buffer and stored at 
-80ºC, until use. For Western blot analysis, cells were 
previously exposed to hypoxia for 24h.
Extracellular glucose and lactate measurements
Cells were plated in 48 well plates at a density of 
3x104 cells per well and allowed to adhere overnight. 
Glucose and lactate content was analyzed in cell culture 
medium after 24h of hypoxia stimulation in treated 
IC
50
/2 CHC value and MCT downregulated cells, using 
commercial kits (Roche and Spinreact, respectively), as 
described [17]. For these time points, the total protein 
(expressed as total biomass) was assessed using the 
sulforhodamine B assay (SRB, TOX-6, Sigma-Aldrich) 
[17]. Results are expressed as total µg/ total biomass.
Cell viability and proliferation assays
U251 and SW1088 cells were plated in 24 well 
plates, at density of 3x104 cells/well and allowed to adhere 
overnight. After 24h of stimulation in hypoxia, cells were 
treated with the IC
50
/2 values of CHC (4mM in U251 and 
Table 4: Details about primary antibodies and conditions used in immunohistochemistry, immunofluorescence and 
western blot
Protein Company Dilution Clone
MCT1 Chemicon International (AB3538P) 1:200 2424624
MCT4 Santa Cruz Biotechnology (sc-50329) 1:500 C1915
CD147 Santa Cruz Biotechnology (sc-71038) 1:500 F1512
GLUT-1 AbCam (ab15309) 1:500 GR207686-2
CAIX AbCam (ab15086) 1:2000 GR154000-1
HKII AbCam (ab104836) 1:750 GR164816-6
HIF-1α BD Biosciences (610958) 1:100 4115908
β-Actin Santa Cruz Biotechnology (sc-1616) 1:300 I0709
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7.5mM in SW1088 cells, respectively) (Alpha-cyano-4-
hydroxycinnamate, Sigma-Aldrich) in DMEM without 
FBS, under normoxia and hypoxic conditions, during 
48h. After treatment, cells were collected and the effect 
of CHC on cell viability was assessed through trypan 
blue counting. For cell proliferation analysis, cells were 
plated into 96-well plates, at a density of 3x103 cells per 
well and treated with CHC using the same conditions that 
described for trypan blue assay. After CHC treatment, cells 
were incubated with BrdU and incorporation was assessed 
at 450nm (λref=655nm), according to the manufacturer’s 
protocol (BrdU, Cell Proliferation ELISA; Roche 
Diagnostics). Cell viability (trypan blue assay) and cell 
proliferation for downregulated MCT1 glioma cells, were 
performed as described above.
Wound-healing assay
Cells were seeded in 6-well plates and cultured to 
at least 95% confluence and wound-healing assay was 
performed as described previously [17]. Treatment with 
IC
50
/2 value of CHC and MCT1 downregulation were 
performed during 24h in hypoxia. Wound areas were 
photographed at 0 and 24 hours.
Invasion assay
Cell invasion of U251 and SW1088 cells was assessed 
using 24 well BD Biocoat Matrigel Invasion Chambers 
(354480, BD Biosciences), as previously described [17, 50]. 
Before seeding on rehydratated Matrigel Matrix Chambers, 
cells were grown in 6-well plates in hypoxia and normoxia 
conditions during 24 hours. After that, U251 and SW1088 
cells, at a density of 2.5x104 cell per well in DMEM without 
FBS plus CHC treatment (IC
50
/2 values) were added to 
each insert. The same procedure was followed for MCT1 
silenced cells. After 24hours, non-invading cells were 
removed and invading cells were fixed with methanol and 
stained with hematoxylin.
Spheroid formation
To form spheroids, 2×103 SW1088 cells were 
seeded in agarose-coated 48-well plates in 200µl of 
DMEM supplemented media. Spheroids were incubated, 
under shaking, at 37°C in a humidified atmosphere of 5% 
CO2 for 11 days. Fresh culture media was added every 48 
hours. At day 15, intact spheroids were collected, fixed 
with 4% paraformaldehyde and embedded in paraffin for 
IHC analyses, as previously described.
Chicken chorioallantoic membrane (CAM) assay
CAM assay was performed as described previously 
[17, 51]. U251 cells (2x106 cells) in Matrigel were 
placed at 10 day of embryo development on the CAM 
and allowed to growth for 7 days. After that, CAMs with 
tumors were dissected, fixed in 4% paraformaldehyde 
at room temperature and included in paraffin. 
Immunohistochemistry for MCT1, MCT4 and CAIX 
on paraffin sections of microtumors was performed as 
previously described for human samples.
Orthotopic GBM xenografts
All experiments with mice were approved by 
institutional and national ethical committees (Direção Geral 
de Alimentação e Veterinária, Portugal) and in accordance 
with European Union Directive 2010/63/ EU. For intracranial 
models, a total of 2x105 U87-MG cells were stereotactically 
injected in the brain striatum (1.8mm medial-lateral right, 
0.4mm anterior-posterior, and 2.5mm dorsal-ventral from the 
bregma) of 8 weeks old athymic nude Foxn1nu male mice, as 
previously described [52]. Animal body weight was evaluated 
3 times per week, and general behavior and symptomatology 
daily. Brains were collected for immunofluorescence 
analyses, for which samples were fixed by immersion in 
formalin and subsequently embedded in paraffin.
Tissues samples
A total of 45 formalin-fixed paraffin embedded 
(FFPE) GBM (WHO grade IV) and 17 non-tumoral 
adjacent tissues were obtained from the Department 
of Pathology of Hospital Pedro Hispano, Matosinhos, 
Centro Hospitalar do Porto, Porto, and Hospital Dr. Nélio 
Mendonça, Madeira, Portugal. All procedures described 
in this study were in accordance with national and 
institutional ethical standards and previously approved by 
Local Ethical Review Committees.
Statistical analysis
Data from human tissues were analyzed using SPSS 
statistical software (version 22, SPSS Inc). Comparison 
of expression of the different markers was evaluated for 
statistical significance using Pearson’s chi square (χ2) test 
with the threshold for significance being p≤0.05. For the 
in vitro studies, the GraphPad prism 5 software was used, 
with the Student’s t test, considering significant values 
p≤0.05.
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
FUNDING
This study was supported by Projecto Estratégico- 
LA 26 – 2013-2014 (PEst-C/SAL/LA0026/2013) and 
ON.2 SR&TD Integrated Program (NORTE-07-0124-
FEDER-000017)” co-funded by Programa Operacional 
Regional do Norte (ON.2- O Novo Norte), Quadro de 
Referência Estratégico Nacional (QREN), through Fundo 
Oncotarget46351www.impactjournals.com/oncotarget
Europeu de Desenvolvimento Regional (FEDER), as well 
as MCTI/CNPq Nº 73/2013 (Brazil). VMG received a 
fellowship from Fundação para a Ciência e Tecnologia 
(FCT) ref. SFRH/BD/51997/2012.
Author contributions
VMG participated in the conception, design 
and writing of the manuscript, acquisition, analysis 
and interpretation of data, as well as development of 
methodology; SG, OM and MP performed some of the 
assays; MH contributed to data analysis of human samples; 
BMC contributed to data interpretation, manuscript 
revision and supply of the U87-MG orthotopic samples; 
MMP, CP, MC, GB and PC contributed to material supply 
particularly of human samples; RMR and FB participated 
in the conception of the study, data interpretation, revision 
of the manuscript and work supervision.
REFERENCES
1. Hanahan D and Weinberg RA. Hallmarks of cancer: the 
next generation. Cell. 2011; 144:646-674.
2. Cairns RA, Harris IS and Mak TW. Regulation of cancer 
cell metabolism. Nature reviews Cancer. 2011; 11:85-95.
3. Warburg O. On respiratory impairment in cancer cells. 
Science. 1956; 124:269-270.
4. Gatenby RA and Gillies RJ. Why do cancers have high 
aerobic glycolysis? Nature reviews Cancer. 2004; 4:891-899.
5. Denko NC. Hypoxia, HIF1 and glucose metabolism in the 
solid tumour. Nature reviews Cancer. 2008; 8:705-713.
6. Chiche J, Brahimi-Horn MC and Pouyssegur J. Tumour 
hypoxia induces a metabolic shift causing acidosis: a 
common feature in cancer. Journal of cellular and molecular 
medicine. 2010; 14:771-794.
7. Hirschhaeuser F, Sattler UG and Mueller-Klieser W. 
Lactate: a metabolic key player in cancer. Cancer research. 
2011; 71:6921-6925.
8. Riemenschneider MJ and Reifenberger G. Molecular 
neuropathology of gliomas. International journal of 
molecular sciences. 2009; 10:184-212.
9. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn 
MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger 
K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, 
Mokhtari K, et al. Effects of radiotherapy with concomitant 
and adjuvant temozolomide versus radiotherapy alone on 
survival in glioblastoma in a randomised phase III study: 
5-year analysis of the EORTC-NCIC trial. The lancet 
oncology. 2009; 10:459-466.
10. Wolf A, Agnihotri S and Guha A. Targeting metabolic 
remodeling in glioblastoma multiforme. Oncotarget. 2010; 
1:552-562. doi: 10.18632/oncotarget.190.
11. Oudard S, Arvelo F, Miccoli L, Apiou F, Dutrillaux AM, 
Poisson M, Dutrillaux B and Poupon MF. High glycolysis 
in gliomas despite low hexokinase transcription and activity 
correlated to chromosome 10 loss. British journal of cancer. 
1996; 74:839-845.
12. Tabatabaei P, Bergstrom P, Henriksson R and Bergenheim 
AT. Glucose metabolites, glutamate and glycerol in 
malignant glioma tumours during radiotherapy. Journal of 
neuro-oncology. 2008; 90:35-39.
13. Izumi H, Torigoe T, Ishiguchi H, Uramoto H, Yoshida Y, 
Tanabe M, Ise T, Murakami T, Yoshida T, Nomoto M and 
Kohno K. Cellular pH regulators: potentially promising 
molecular targets for cancer chemotherapy. Cancer 
treatment reviews. 2003; 29:541-549.
14. Halestrap AP. The monocarboxylate transporter family-
-Structure and functional characterization. IUBMB life. 
2012; 64:1-9.
15. Halestrap AP and Wilson MC. The monocarboxylate 
transporter family--role and regulation. IUBMB life. 2012; 
64:109-119.
16. Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal 
M, Schmitt FC and Baltazar F. Role of monocarboxylate 
transporters in human cancers: state of the art. Journal of 
bioenergetics and biomembranes. 2012; 44:127-139.
17. Miranda-Goncalves V, Honavar M, Pinheiro C, Martinho 
O, Pires MM, Pinheiro C, Cordeiro M, Bebiano G, Costa 
P, Palmeirim I, Reis RM and Baltazar F. Monocarboxylate 
transporters (MCTs) in gliomas: expression and exploitation 
as therapeutic targets. Neuro-oncology. 2013; 15:172-188.
18. Halestrap AP. Monocarboxylic acid transport. 
Comprehensive Physiology. 2013; 3:1611-1643.
19. Kim JW, Gao P and Dang CV. Effects of hypoxia on tumor 
metabolism. Cancer metastasis reviews. 2007; 26:291-298.
20. Ord JJ, Streeter EH, Roberts IS, Cranston D and Harris AL. 
Comparison of hypoxia transcriptome in vitro with in vivo 
gene expression in human bladder cancer. Br J Cancer. 
2005; 93:346-354.
21. Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax 
J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Diepart 
C, Jordan BF, Kelley MJ, Gallez B, Wahl ML, Feron O 
and Dewhirst MW. Targeting lactate-fueled respiration 
selectively kills hypoxic tumor cells in mice. J Clin Invest. 
2008; 118:3930-3942.
22. Cheng C, Edin NF, Lauritzen KH, Aspmodal I, 
Christoffersen S, Jian L, Rasmussen LJ, Pettersen 
EO, Xiaoqun G and Bergersen LH. Alterations of 
monocarboxylate transporter densities during hypoxia in 
brain and breast tumour cells. Cell Oncol (Dordr). 2012; 
35:217-227.
23. Doyen J, Trastour C, Ettore F, Peyrottes I, Toussant N, Gal 
J, Ilc K, Roux D, Parks SK, Ferrero JM and Pouyssegur 
J. Expression of the hypoxia-inducible monocarboxylate 
transporter MCT4 is increased in triple negative breast 
cancer and correlates independently with clinical outcome. 
Biochemical and biophysical research communications. 
2014; 451:54-61.
Oncotarget46352www.impactjournals.com/oncotarget
24. McClelland GB and Brooks GA. Changes in MCT 1, MCT 
4, and LDH expression are tissue specific in rats after long-
term hypobaric hypoxia. Journal of applied physiology. 
2002; 92:1573-1584.
25. Kay HH, Zhu S and Tsoi S. Hypoxia and lactate production 
in trophoblast cells. Placenta. 2007; 28:854-860.
26. Perez de Heredia F, Wood IS and Trayhurn P. Hypoxia 
stimulates lactate release and modulates monocarboxylate 
transporter (MCT1, MCT2, and MCT4) expression in 
human adipocytes. Pflugers Archiv : European journal of 
physiology. 2010; 459:509-518.
27. Ullah MS, Davies AJ and Halestrap AP. The plasma 
membrane lactate transporter MCT4, but not MCT1, is 
up-regulated by hypoxia through a HIF-1alpha-dependent 
mechanism. J Biol Chem. 2006; 281:9030-9037.
28. Zhang F, Vannucci SJ, Philp NJ and Simpson IA. 
Monocarboxylate transporter expression in the spontaneous 
hypertensive rat: effect of stroke. J Neurosci Res. 2005; 
79:139-145.
29. Linnik IV, Scott ML, Holliday KF, Woodhouse N, Waterton 
JC, O’Connor JP, Barjat H, Liess C, Ulloa J, Young H, Dive 
C, Hodgkinson CL, Ward T, Roberts D, Mills SJ, Thompson 
G, et al. Noninvasive tumor hypoxia measurement using 
magnetic resonance imaging in murine U87 glioma 
xenografts and in patients with glioblastoma. Magnetic 
resonance in medicine. 2014; 71:1854-1862.
30. Jensen RL. Brain tumor hypoxia: tumorigenesis, 
angiogenesis, imaging, pseudoprogression, and as a 
therapeutic target. Journal of neuro-oncology. 2009; 
92:317-335.
31. Yang L, Lin C, Wang L, Guo H and Wang X. Hypoxia 
and hypoxia-inducible factors in glioblastoma multiforme 
progression and therapeutic implications. Experimental cell 
research. 2012; 318:2417-2426.
32. Boidot R, Vegran F, Meulle A, Le Breton A, Dessy C, 
Sonveaux P, Lizard-Nacol S and Feron O. Regulation of 
monocarboxylate transporter MCT1 expression by p53 
mediates inward and outward lactate fluxes in tumors. 
Cancer research. 2012; 72:939-948.
33. Halestrap AP and Meredith D. The SLC16 gene family-
from monocarboxylate transporters (MCTs) to aromatic 
amino acid transporters and beyond. Pflugers Archiv : 
European journal of physiology. 2004; 447:619-628.
34. Halestrap AP. Transport of pyruvate nad lactate into human 
erythrocytes. Evidence for the involvement of the chloride 
carrier and a chloride-independent carrier. The Biochemical 
journal. 1976; 156:193-207.
35. Marchiq I, Le Floch R, Roux D, Simon MP and Pouyssegur 
J. Genetic disruption of lactate/H+ symporters (MCTs) and 
their subunit CD147/BASIGIN sensitizes glycolytic tumor 
cells to phenformin. Cancer research. 2015; 75:171-180.
36. Morais-Santos F, Miranda-Goncalves V, Pinheiro S, Vieira 
AF, Paredes J, Schmitt FC, Baltazar F and Pinheiro C. 
Differential sensitivities to lactate transport inhibitors of 
breast cancer cell lines. Endocrine-related cancer. 2014; 
21:27-38.
37. Brandsma D and van den Bent MJ. Molecular targeted 
therapies and chemotherapy in malignant gliomas. Current 
opinion in oncology. 2007; 19:598-605.
38. Colen CB, Shen Y, Ghoddoussi F, Yu P, Francis TB, Koch 
BJ, Monterey MD, Galloway MP, Sloan AE and Mathupala 
SP. Metabolic targeting of lactate efflux by malignant 
glioma inhibits invasiveness and induces necrosis: an 
in vivo study. Neoplasia. 2011; 13:620-632.
39. Gallagher SM, Castorino JJ and Philp NJ. Interaction of 
monocarboxylate transporter 4 with beta1-integrin and its 
role in cell migration. American journal of physiology Cell 
physiology. 2009; 296:C414-421.
40. Fujiwara S, Nakagawa K, Harada H, Nagato S, Furukawa 
K, Teraoka M, Seno T, Oka K, Iwata S and Ohnishi T. 
Silencing hypoxia-inducible factor-1alpha inhibits cell 
migration and invasion under hypoxic environment in 
malignant gliomas. International journal of oncology. 2007; 
30:793-802.
41. Coady MJ, Chang MH, Charron FM, Plata C, Wallendorff 
B, Sah JF, Markowitz SD, Romero MF and Lapointe JY. 
The human tumour suppressor gene SLC5A8 expresses 
a Na+-monocarboxylate cotransporter. The Journal of 
physiology. 2004; 557:719-731.
42. Grillon E, Farion R, Fablet K, De Waard M, Tse CM, 
Donowitz M, Remy C and Coles JA. The spatial 
organization of proton and lactate transport in a rat brain 
tumor. PloS one. 2011; 6:e17416.
43. Rademakers SE, Lok J, van der Kogel AJ, Bussink J and 
Kaanders JH. Metabolic markers in relation to hypoxia; 
staining patterns and colocalization of pimonidazole, HIF-
1alpha, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC 
cancer. 2011; 11:167.
44. Oliver L, Olivier C, Marhuenda FB, Campone M 
and Vallette FM. Hypoxia and the malignant glioma 
microenvironment: regulation and implications for 
therapy. Current molecular pharmacology. 2009; 
2:263-284.
45. Flynn JR, Wang L, Gillespie DL, Stoddard GJ, Reid JK, 
Owens J, Ellsworth GB, Salzman KL, Kinney AY and 
Jensen RL. Hypoxia-regulated protein expression, patient 
characteristics, and preoperative imaging as predictors of 
survival in adults with glioblastoma multiforme. Cancer. 
2008; 113:1032-1042.
46. Proescholdt MA, Merrill MJ, Stoerr EM, Lohmeier A, 
Pohl F and Brawanski A. Function of carbonic anhydrase 
IX in glioblastoma multiforme. Neuro-oncology. 2012; 
14:1357-1366.
47. Pinheiro C, Sousa B, Albergaria A, Paredes J, Dufloth R, 
Vieira D, Schmitt F and Baltazar F. GLUT1 and CAIX 
expression profiles in breast cancer correlate with adverse 
prognostic factors and MCT1 overexpression. Histology 
and histopathology. 2011; 26:1279-1286.
Oncotarget46353www.impactjournals.com/oncotarget
48. Meijer TW, Schuurbiers OC, Kaanders JH, Looijen-
Salamon MG, de Geus-Oei LF, Verhagen AF, Lok J, van 
der Heijden HF, Rademakers SE, Span PN and Bussink J. 
Differences in metabolism between adeno- and squamous 
cell non-small cell lung carcinomas: spatial distribution and 
prognostic value of GLUT1 and MCT4. Lung cancer. 2012; 
76:316-323.
49. Morais-Santos F, Granja S, Miranda-Goncalves V, Moreira 
AH, Queiros S, Vilaca JL, Schmitt FC, Longatto-Filho 
A, Paredes J, Baltazar F and Pinheiro C. Targeting lactate 
transport suppresses in vivo breast tumour growth. Oncotarget. 
2015; 6:19177-19189. doi: 10.18632/oncotarget.3910.
50. Moniz S, Martinho O, Pinto F, Sousa B, Loureiro C, 
Oliveira MJ, Moita LF, Honavar M, Pinheiro C, Pires M, 
Lopes JM, Jones C, Costello JF, Paredes J, Reis RM and 
Jordan P. Loss of WNK2 expression by promoter gene 
methylation occurs in adult gliomas and triggers Rac1-
mediated tumour cell invasiveness. Human molecular 
genetics. 2013; 22:84-95.
51. Martinho O, Pinto F, Granja S, Miranda-Goncalves 
V, Moreira MA, Ribeiro LF, di Loreto C, Rosner MR, 
Longatto-Filho A and Reis RM. RKIP inhibition in 
cervical cancer is associated with higher tumor aggressive 
behavior and resistance to cisplatin therapy. PloS one. 2013; 
8:e59104.
52. Pojo M, Goncalves CS, Xavier-Magalhaes A, Oliveira AI, 
Goncalves T, Correia S, Rodrigues AJ, Costa S, Pinto L, 
Pinto AA, Lopes JM, Reis RM, Rocha M, Sousa N and 
Costa BM. A transcriptomic signature mediated by HOXA9 
promotes human glioblastoma initiation, aggressiveness 
and resistance to temozolomide. Oncotarget. 2015; 6:7657-
7674. doi: 10.18632/oncotarget.3150.
